VRTX:NGS-Vertex Pharmaceuticals Incorporated (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 491.62

Change

+5.63 (+1.16)%

Market Cap

USD 21.38B

Volume

0.85M

Analyst Target

USD 306.43
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

+1.39 (+0.13%)

USD 117.19B
MRNA Moderna Inc

+0.38 (+0.32%)

USD 46.95B
ARGX argenx NV ADR

+6.66 (+1.31%)

USD 30.45B
ALNY Alnylam Pharmaceuticals Inc

+3.65 (+1.56%)

USD 29.58B
BGNE BeiGene Ltd

+9.60 (+6.12%)

USD 16.93B
RPRX Royalty Pharma Plc

-0.37 (-1.30%)

USD 16.81B
BMRN Biomarin Pharmaceutical Inc

-0.06 (-0.07%)

USD 15.97B
UTHR United Therapeutics Corporatio..

-24.25 (-7.18%)

USD 14.60B
SRPT Sarepta Therapeutics Inc

-0.80 (-0.56%)

USD 13.76B
INCY Incyte Corporation

-2.72 (-4.01%)

USD 12.98B

ETFs Containing VRTX

DCCHAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

+0.58 (+0.00%)

USD 0.08B
DCUSAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

+0.53 (+0.00%)

N/A
DCEUAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

+0.14 (+0.00%)

N/A
DCGBAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 8.39 % 0.00 %

+0.13 (+0.00%)

USD 7.04M
MSGR 8.22 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 7.99 % 0.00 %

+0.18 (+0.00%)

N/A
2B70:F iShares NASDAQ US Biotech.. 7.95 % 0.00 %

N/A

USD 0.52B
BTEC:SW iShares Nasdaq US Biotech.. 7.95 % 0.00 %

-0.03 (0.00%)

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 7.80 % 0.00 %

+0.03 (+0.00%)

USD 0.52B
UBIO 6.52 % 0.95 %

N/A

N/A
LIFE-U:CA 5.49 % 0.00 %

N/A

N/A
LIFE-B:CA Evolve Global Healthcare .. 5.49 % 0.00 %

-0.09 (0.00%)

N/A
ZWHC:CA BMO Covered Call Health C.. 5.16 % 0.00 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 5.03 % 0.57 %

-0.26 (0.00%)

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.94 % 0.00 %

+0.38 (+0.00%)

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.91 % 0.00 %

+0.52 (+0.00%)

N/A
XNNS:LSE Xtrackers MSCI Innovation.. 4.83 % 0.00 %

+0.62 (+0.00%)

N/A
XNNV:LSE Xtrackers MSCI Innovation.. 4.83 % 0.00 %

+0.84 (+0.00%)

N/A
XNNV:XETRA Xtrackers MSCI Innovation.. 4.76 % 0.00 %

+0.77 (+0.00%)

N/A
XDG3:XETRA Xtrackers MSCI Global SDG.. 4.62 % 0.00 %

+0.23 (+0.00%)

USD 0.13B
FTXH First Trust Nasdaq Pharma.. 4.08 % 0.60 %

-0.40 (0.00%)

USD 0.02B
SAMM The Advisors’ Inner .. 3.81 % 0.00 %

N/A

N/A
XDGI:XETRA Xtrackers MSCI Global SDG.. 3.63 % 0.00 %

+0.34 (+0.00%)

USD 0.02B
HEAL:CA 3.39 % 0.00 %

N/A

N/A
CDNA:CA 3.13 % 0.00 %

N/A

N/A
ETLI:XETRA L&G Pharma Breakthrough U.. 2.68 % 0.00 %

+0.07 (+0.00%)

USD 0.02B
BIOT:SW L&G Pharma Breakthrough U.. 2.68 % 0.00 %

+0.04 (+0.00%)

N/A
HLTH:AU VanEck Global Healthcare .. 2.48 % 0.00 %

+0.16 (+0.00%)

USD 0.06B
UPWD 2.43 % 0.00 %

N/A

N/A
POWA Invesco Bloomberg Pricing.. 2.11 % 0.00 %

+0.87 (+0.00%)

N/A
XLVE:CA Mulvihill U.S. Health Car.. 1.93 % 0.00 %

N/A

N/A
XMLH:XETRA L&G Healthcare Breakthrou.. 1.76 % 0.00 %

+0.06 (+0.00%)

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 1.76 % 0.00 %

+0.07 (+0.00%)

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 1.76 % 0.00 %

N/A

USD 0.07B
DOCG:LSE L&G Healthcare Breakthrou.. 1.76 % 0.00 %

+5.70 (+0.00%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.76 % 0.00 %

+0.10 (+0.00%)

USD 0.07B
ZUH:CA BMO Equal Weight US Healt.. 1.67 % 0.39 %

-0.33 (0.00%)

CAD 0.27B
MVEA:XETRA iShares Edge MSCI USA Min.. 1.59 % 0.00 %

+0.06 (+0.00%)

USD 0.32B
MVEA:SW iShares Edge MSCI USA Min.. 1.59 % 0.00 %

+0.04 (+0.00%)

USD 0.37B
ESMV iShares ESG MSCI USA Min .. 1.56 % 0.00 %

+0.17 (+0.00%)

USD 0.01B
LABU Direxion Daily S&P Biotec.. 1.51 % 1.14 %

+0.69 (+0.00%)

USD 1.11B
MVEW:LSE iShares Edge MSCI World M.. 1.44 % 0.00 %

+0.05 (+0.00%)

USD 0.53B
MVEW:XETRA iShares Edge MSCI World M.. 1.41 % 0.00 %

+0.05 (+0.00%)

USD 0.78B
MVEC:SW iShares Edge MSCI World M.. 1.41 % 0.00 %

+0.04 (+0.00%)

USD 0.16B
MVEW:SW iShares Edge MSCI World M.. 1.41 % 0.00 %

+0.02 (+0.00%)

USD 0.51B
MVWE:SW iShares Edge MSCI World M.. 1.41 % 0.00 %

N/A

USD 0.07B
FLXU:XETRA Franklin LibertyShares IC.. 1.17 % 0.00 %

+0.46 (+0.00%)

USD 0.18B
FLXU:SW Franklin U.S. Equity UCIT.. 1.17 % 0.00 %

+0.15 (+0.00%)

N/A
THNZ:XETRA L&G Global Thematic ESG E.. 1.03 % 0.00 %

+0.13 (+0.00%)

N/A
SMRT:PA 0.58 % 0.00 %

N/A

N/A
SM8T:XETRA Amundi Index Solutions - .. 0.58 % 0.00 %

+5.00 (+0.00%)

USD 0.04B
SMRU:PA Amundi Index Solutions - .. 0.58 % 0.00 %

+6.24 (+0.00%)

USD 3.35M
BBH VanEck Biotech ETF 0.00 % 0.35 %

+0.02 (+0.00%)

USD 0.44B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-0.24 (0.00%)

USD 0.09B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.07 (+0.00%)

USD 2.95M
DEF 0.00 % 0.59 %

N/A

N/A
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+1.39 (+0.00%)

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

+0.09 (+0.00%)

USD 7.71B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

-0.02 (0.00%)

USD 0.12B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

-0.01 (0.00%)

USD 0.06B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.05 (+0.00%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.02 (+0.00%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+8.45 (+0.00%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.04 (+0.00%)

N/A
VLQ:CA 0.00 % 0.40 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+0.07 (+0.00%)

N/A
ZBIO 0.00 % 0.95 %

N/A

N/A
HWWA:LSE HSBC Multi Factor Worldwi.. 0.00 % 0.00 %

+0.29 (+0.00%)

N/A
SMRG:LSE 0.00 % 0.00 %

N/A

N/A
SMRU:LSE Amundi Index Solutions - .. 0.00 % 0.00 %

+6.54 (+0.00%)

N/A
HWWD:LSE HSBC Multi Factor Worldwi.. 0.00 % 0.00 %

+0.39 (+0.00%)

N/A
VMOM:LSE 0.00 % 0.00 %

N/A

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.05 (+0.00%)

N/A
FLXU:F Franklin LibertyShares IC.. 0.00 % 0.00 %

+0.63 (+0.00%)

N/A
SM8T:F Amundi Index Solutions - .. 0.00 % 0.00 %

+7.00 (+0.00%)

N/A
TGGR:CA TD Active Global Equity G.. 0.00 % 0.00 %

+0.16 (+0.00%)

CAD 0.04B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
ZINN:CA 0.00 % 0.00 %

N/A

N/A
JEPI JPMorgan Equity Premium I.. 0.00 % 0.00 %

+0.44 (+0.00%)

USD 34.20B
NVQ 0.00 % 0.00 %

N/A

N/A
TDOC:CA TD Global Healthcare Lead.. 0.00 % 0.00 %

+0.01 (+0.00%)

CAD 0.09B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

+0.02 (+0.00%)

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.82% 75% C 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.82% 75% C 82% B
Trailing 12 Months  
Capital Gain 42.06% 83% B 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.06% 83% B 88% B+
Trailing 5 Years  
Capital Gain 179.66% 88% B+ 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 179.66% 88% B+ 89% A-
Average Annual (5 Year Horizon)  
Capital Gain 18.84% 74% C 78% C+
Dividend Return 18.84% 74% C 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.92% 91% A- 67% D+
Risk Adjusted Return 69.98% 98% N/A 89% A-
Market Capitalization 21.38B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 30.40 20% 31%
Price/Book Ratio 5.83 25% 20%
Price / Cash Flow Ratio 34.19 3% 8%
Price/Free Cash Flow Ratio 20.00 2% 13%
Management Effectiveness  
Return on Equity 24.38% 98% 92%
Return on Invested Capital 18.99% 89% 87%
Return on Assets 12.82% 99% 97%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.